Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$48.15 USD
0.00 (0.00%)
Updated May 20, 2024 01:51 PM ET
3-Hold of 5 3
C Value D Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
BPMUF 48.15 0.00(0.00%)
Will BPMUF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BPMUF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMUF
Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep going
BPMUF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?
Here's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price Strength